New inhaled drug RCS-21 put to the test in healthy volunteers
NCT ID NCT06752122
First seen Nov 20, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This early-stage trial is checking if a single inhaled dose of RCS-21 is safe and tolerable in 24 healthy adults aged 18 to 64. Participants receive one dose and are closely monitored for side effects. The study does not aim to treat any disease, just to gather initial safety and drug-level information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)
RECRUITINGHanover, 30625, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.